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Abstract
Background: Both osteoarthritis (OA) and cardiovascular diseases (CVD) are prevalent conditions which often co-
exist. Vascular involvement in the pathogenesis of these diseases, as well as increased cardiovascular risk in OA
patients give occasion to investigate arterial stiffness in OA. The aim of this study was to establish associations
between OA and arterial stiffness.
Methods: The characteristics of arterial stiffness were measured with Sphygmocor and HDI devices in 48 patients
(age 63 ± 7 years (mean ± SD)) with end-stage OA awaiting knee and hip replacement and in 49 age and gender
matched controls (61 ± 7 years). Independent Student’s t-test or the Mann-Whitney U test was used to compare
means between the groups. Correlation between variables was determined using Pearson’s or Spearman’s
correlation analysis and stepwise multiple regression analysis.
Results: Carotid-femoral pulse wave velocity (car-fem PWV) was increased in the patients with OA compared to
the controls (9.6 ± 2.4 and 8.4 ± 1.9 m/s, p = 0.015 respectively). High-sensitivity C-reactive protein and white blood
cells count were significantly higher in the OA patients compared with the controls (1.80 ± 1.10 and 1.48 ± 1.32
mg/l, p = 0.042; 6.5 ± 1.5 and 5.6 ± 1.9 109/l, p = 0.001 respectively). In multiple regression analysis age (p < 0.001),
mean arterial blood pressure (p = <0.001) and OA status (p = 0.029) were found to be independent predictors of
car-fem PWV.
Conclusions: This study showed that patients with OA had increased aortic stiffness compared to non-OA controls.
The potential link between arterial stiffening and OA suggests that vascular alterations are involved in OA pathogenesis
and could be responsible for increased cardiovascular risk in end-stage OA patients.
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Background
Osteoarthritis (OA) is a chronic progressive disease that
affects the whole joint: cartilage, bone, joint capsule, syn-
ovial membrane, ligaments and periarticular muscles.
Due to overweight and aging populations, the disease
has a huge and growing socioeconomic impact [1]. Knee
OA alone affects more than 250 million people world-
wide [2]. OA patients have increased cardiovascular risk
[3–5]. In a prospective study, Barbour et al. [4] found
that radiographic hip OA increased cardiovascular
mortality by 25 % and all-cause mortality by 43 %. Simi-
larly, in a prospective longitudinal study, Rahman et al.
[6] found OA to be associated with higher risk of ische-
mic heart disease. However, it remains to be elucidated
whether OA and cardiovascular diseases (CVD) are
causally related, or whether this association is due to
shared risk factors.
Arterial stiffness is an established marker of increased
cardiovascular risk [7, 8] but it has rarely been studied
in OA patients. There is evidence that hand OA, a more
systemic form of OA, is related to increased arterial stiff-
ness [9]. In contrast, a study of 206 patients with symp-
tomatic knee OA found no association between arterial
stiffness and bone marrow lesions, a surrogate marker
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for OA [10]. However, the data about possible interac-
tions between OA and arterial stiffness are contradictory
and need further research.
Many mechanisms responsible for OA pathogenesis
are also involved in development of vascular damage.
Common risk factors include aging, obesity and limited
physical activity, as well as high exposure to non-
steroidal anti-inflammatory drugs that increase CVD
risk. Also, excessive oxidative stress has been found to
occur in patients with OA [11, 12]. Oxidative stress has
a significant role in development of OA by promoting
inflammation, cellular senescence and apoptosis [13].
Chronic low-grade inflammation is crucial in deterior-
ation of OA joints [14, 15]. Analogously, arterial stiffness
and endothelial dysfunction have also been found to be
associated with oxidative stress [16, 17] and inflamma-
tion [18, 19]. Obesity is considered a risk factor for both
OA and CVD. Adipose tissue produces cytokines and
adipokines that damage cartilage and arteries [20, 21].
Thus, there is a potential pathogenetic link between OA
and increased arterial stiffness via inflammation and oxi-
dative stress. The aim of this present study was to eluci-
date, besides conventional cardiovascular risk factors,
also the role of arterial stiffness in patients with OA.
Methods
Study population
Patients, with primary knee or hip OA, who were eli-
gible for total joint replacement at Tartu University
Hospital, Estonia in 2014–2015, were included. The
OA was assessed using the American College of Rheu-
matology’s criteria for knee and hip OA [22, 23]. Our
study includes both knee and hip OA and focuses on
systemic changes that accompany OA. Subjects with
pre-existing hypertension were included. Patients with
any acute or chronic inflammatory disease, diabetes,
coronary artery disease, cardiac arrhythmias or known
valve pathology, peripheral atherosclerotic disease, ma-
lignancies or renal insufficiency (eGFR < 60 ml/min/
1.73 m2) were excluded.
Age and sex matched controls with no prior joint
problems were selected from family medical practices.
The family medical practices are in the catchment area
of Tartu University Hospital. Selection was made, using
the group matching strategy, on the basis of clinical
examination and not on plain radiography, which is
known to be insensitive to early OA [24] and correlates
poorly with patients’ disability (pain, function) and dis-
ease severity [25]. The exclusion criteria for the control
group were (based on interviews, clinical examinations
and blood tests): any concomitant acute or chronic in-
flammatory disease, a visit to their family practitioner
due to hip or knee joint complaints, any persistent knee
or hip joint pain, diabetes, coronary artery disease,
cardiac arrhythmia, cerebrovascular or peripheral artery
disease, malignancies and renal insufficiency.
The study was conducted according to the Helsinki
declaration and received approval from the Ethics Com-
mittee of the University of Tartu. Written informed con-
sent was obtained from all participants.
Study protocol
Blood samples were collected from the antecubital fossa
between 07:00–11:00 after an overnight fast and abstin-
ence from tobacco. Study participants’ height, weight,
waist and hip circumference were recorded and joint-
specific evaluation was performed. The Harris Hip Score
(HHS) was used for hip joint evaluation and the Hospital
for Special Surgery (HSS) Knee Score was used for knee
joint evaluation. Both of these tests have a scale of 0–
100, where 100 is the best possible outcome. After
15 min of rest in a temperature controlled quiet room in
a supine position, participants’ blood pressure and pulse
wave velocity (PWV) were recorded and pulse wave ana-
lysis was made. All pulse wave parameters were mea-
sured at least twice and the average was calculated.
Hemodynamic measurements
Blood pressure was measured using a digital oscillometric
device (A&D UA-767; A&D Company Ltd., Tokyo, Japan)
and the mean of three readings was recorded. Mean arter-
ial pressure was obtained by integration of the radial pres-
sure waveform using the SphygmoCor software (SCOR
Px, 7.0; AtCor Medical, Sydney, Australia). Arterial stiff-
ness was measured using pulse wave analysis and PWV.
Left radial artery waveforms were recorded with a high fi-
delity micromanometer (SPT-301BH; Millar Instruments,
Tx., USA). Corresponding ascending aortic waveforms
were then generated using a transfer function to calculate
central hemodynamics and the augmentation index (AIx).
The AIx was corrected for a heart rate of 75 beats per mi-
nute. Carotid-femoral (car-fem) and carotid-radial (car-
rad) PWV were measured by sequentially recording ECG-
gated carotid and femoral or radial artery waveforms using
a Sphygmocor device (SphygmoCor; AtCor Medical, Syd-
ney, Australia) and the foot-to-foot method [26]. The
pulse waveform was recorded from the right radial artery
with a Cardiovascular Profiling Instrument (HDI/Pulse
Wave CR-2000; Hypertension Diagnostics Inc., Eagan,
USA) which measures large (C1) and small (C2) artery
elasticity.
Laboratory analysis
Plasma glucose, complete blood count, triglycerides,
total cholesterol, LDL-cholesterol and HDL-cholesterol,
creatinine and urea were measured by standard labora-
tory methods, using certified assays, in a local clinical
laboratory.
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Radiographic evaluation
Standard weight-bearing antero-posterior knee and hip
joint radiographs were taken in the OA group, no radio-
graphs were taken in the control group. Osteoarthritis
was assessed according to the Kellgren-Lawrence grad-
ing system, where: 0 = no changes; 1 = doubtful joint
space narrowing; 2 = definite osteophytes and doubtful
joint space narrowing; 3 = definite ostephytes, joint space
narrowing, sclerosis and possible deformity; 4 =marked
joint space narrowing, large osteophytes, severe sclerosis
and definite bone deformity [27]. The radiographs were
evaluated independently by two raters blinded to the
clinical data and a consensus score was used.
Statistical analysis
The statistical analysis software SPSS 22.0 (SPSS Inc.,
Chicago IL, USA) for windows was used for data ana-
lysis. The Shapiro- Wilk test was used to ascertain
whether variables were normally distributed. Continuous
variables are presented as means with ± standard devi-
ation. Dichotomous variables are presented as preva-
lence in number. A two tailed Student’s t-test was used
for detecting differences between the groups for nor-
mally distributed data and logarithmic transformation or
Mann-Whitney U test was used for non-parametric data.
Pearson’s correlation coefficient and Spearman’s rho
were used to identify associations between continuous
variables within the study groups. A Chi-square test or
Fischer’s exact test was used to compare group propor-
tions where appropriate. Multiple linear regression ana-
lyses with the use of a forward and backward stepwise
variable selection procedure, wereperformed to investigate
the independent associations between variables. The au-
thors set the goal to detect a difference of 1 m/s in car-
fem PWV. The standard deviation for the study group
was estimated at 2.0. Statistical power calculations showed
that group size had to be n = 41 for either group with an
Alpha error level of 5 % and a Beta error level of 20 %. In
order to further minimize Beta error level the number of
subjects was increased to 48 + 49. Interrater reliability ana-
lysis, with the use of intraclass correlation coefficient
(ICC), was performed to determine consistency among
the raters of radiographic severity of OA.
Results
The study population consisted of a total of 97 partici-
pants of whom 48 were with hip or knee osteoarthritis
and 49 were healthy volunteers. The general anthropo-
metric characteristics of the participants are presented
in Table 1. Both groups had approximately the same age,
BMI, male to female ratio, waist to hip ratio and number
of active smokers. The OA group included 23 subjects
and the control group included 19 subjects with hyper-
tension, of whom 10 in either group were using hyper-
tension medications. There was a clear difference in
HHS and HSS Knee Score between the groups: both
were significantly higher in the control group. The me-
dian radiographic Kellgren-Lawrence score in the OA
group was 3 (range 2–4). The ICC for the raters was
found to be ICC = 0.73, 95 % CI (0.53-0.85).
Hemodynamics
There was a significant difference between the OA pa-
tients and the controls in central arterial stiffness
Table 1 General parameters of osteoarthritis patients and controls
Variable Osteoarthritis (n = 48) Controls (n = 49) P-value
Age (years) 63 ± 7 61 ± 7 0.115
Male/Female (n) 25/23 24/25 0.760
Height (cm) 1.71 ± 0.10 1.72 ± 0.10 0.508
Weight (kg) 80.8 ± 12.6 78.8 ± 15.1 0.487
BMI (kg/m2) 27.6 ± 3.0 26.4 ± 3.4 0.068
Waist circumference (cm) 96 ± 10 92 ± 12 0.046
Hip circumference (cm) 104 ± 7 102 ± 6 0.387
W/H- ratio 0.92 ± 0.08 0.90 ± 0.10 0.137
Current smoker (n, %) 10 (14) 7 (21) 0.430




Harris Hip score 39 (33–47) 100 (100–100) <0.001
HSS Knee score 62 (49–65) 100 (100–100) <0.001
The values are expressed as means ± s.d. or medians (with interquartile range)
Abbreviations: BMI body-mass index, W/H-ratio waist to hip ratio, HSS Hospital for Special Surgery
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parameter. Car-fem PWV was significantly higher in the
OA group compared to controls (Table 2). Central blood
pressure and peripheral blood pressure did not differ
significantly between the study groups. There was no
significant difference in pulse pressure amplification, or
in C1 and C2 levels between the OA and non-OA
groups. There was significant difference in car-fem PWV
between the hip and the knee OA patients (9.2 ± 2.0 and
10.6 ± 2.7 m/s, p = 0.042).
Laboratory analysis
The results of laboratory analysis are presented in
Table 2. Triglyceride level was significantly higher in the
OA patients compared to the controls. The levels of
LDL and HDL-cholesterol, glucose, urea and eGFR did
not differ between the groups. High-sensitivity C-
reactive protein (hsCRP) and white blood cells count
were significantly higher in the OA group and the differ-
ence in platelet count was of borderline significance.
In the OA patients, serum urea level correlated posi-
tively with car-fem PWV (Fig. 1) and central systolic
blood pressure (Fig. 2). There were no associations be-
tween parameters of arterial stiffness and urea in the
control group. In multiple regression analysis (Table 3),
where car-fem PWV was set as the dependent variable,
age (p < 0.001), mean arterial blood pressure (p = <0.001)
and OA status (p = 0.029) were found to be independent
predictors while urea was not significant (p = 0.233).
Discussion
The results of this case-control study demonstrate that
OA patients have increased central arterial stiffness
compared to non-OA controls. The study gives a com-
prehensive overview of arterial stiffness measured, with
the use of different validated methods in end-stage OA
patients and controls. The study used both patient re-
lated outcome measure and (SF36) and physician related
outcome measures. To the best of our knowledge, this is
the first study to demonstrate increased level of car-fem
PWV- gold standard measure of arterial stiffness- in hip
and knee OA patients.
Table 2 Hemodynamic and laboratory analysis parameters of osteoarthritis patients and healthy controls
Variable Osteoarthritis patients (n = 48) Controls (n = 49) p-value
Peripheral SBP (mm Hg) 133.6 ± 17.8 128.3 ± 18.9 0.158
Peripheral DBP (mm Hg) 80.8 ± 7.5 78.9 ± 9.0 0.269
AIx@HR75 (%) 25.0 ± 8.1 22.8 ± 9.4 0.213
PP amplification (%) 123 ± 11 124 ± 13 0.879
Central SBP (mm Hg) 125.2 ± 17.0 120.5 ± 18.8 0.205
Central DBP (mm Hg) 81.5 ± 8.2 79.8 ± 9.3 0.373
Mean pressure (mm Hg) 99.6 ± 10.9 96.6 ± 12.2 0.209
Heart rate (bpm) 64.8 ± 7.1 63.2 ± 7.3 0.279
car-fem PWV (m/s) 9.6 ± 2.4 8.4 ± 1.9 0.015
car-rad PWV (m/s) 8.7 ± 1.1 8.4 ± 1.1 0.235
C1 (ml/mmHg × 100) 12.5 ± 4.2 12.7 ± 3.5 0.371
C2 (ml/mmHg × 100) 4.5 ± 2.9 5.6 ± 4.3 0.315
Triglycerides (mmol/l) 1.7 ± 0.8 1.4 ± 0.7 0.021
LDL- cholesterol (mmol/l) 4.1 ± 1.0 3.8 ± 1.0 0.234
HDL- cholesterol (mmol/l) 1.5 ± 0.5 1.7 ± 0.5 0.830
Total cholesterol (mmol/l) 6.0 ± 1.1 6.0 ± 1.3 0.264
Glucose (mmol/l) 5.8 ± 0.7 5.7 ± 0.4 0.566
hsCRP (mg/l) 1.80 ± 1.10 1.48 ± 1.32 0.042
Urea (mmol/l) 5.9 ± 2.0 5.3 ± 1.3 0.171
eGFR (ml/mg/1.73 m2) 83 ± 20 82 ± 12 0.434
White blood cells (109/L) 6.5 ± 1.5 5.6 ± 1.9 0.001
Plateletes (109/L) 243 ± 52 222 ± 39 0.053
The values are expressed as means ± s.d
Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure, AIx@HR75 augmentation index corrected for a heart rate of 75 beats per minute, AP aortic
augmentation, car-fem PWV carotid to femoral pulse wave velocity, car-rad PWV carotid to radial pulse wave velocity, C1 large artery elasticity index, C2 small
artery elasticity index, LDL low-density lipoprotein, HDL high-density lipoprotein, hs-CRP high-sensitivity C-reactive protein, eGFR estimated glomerular
filtration rate
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Stiffening of the arteries causes an increase in systolic
and a decrease in diastolic pressure [28]. Rise in systolic
pressure increases the cardiac afterload while lower dia-
stolic pressure reduces coronary perfusion [29]. Arterial
stiffness is one of the main determinants of cardiovascu-
lar risk and has been found to be an independent risk
factor for the development of CVD and increased mor-
tality in many epidemiological studies [30–32]. Imple-
mentation of arterial stiffness assessment into clinical
practice helps identify patients with higher cardiovascu-
lar risk [32]. Car-fem PWV is the gold standard method
for quantifying arterial stiffness and has been accepted
as an intermediate endpoint for cardiovascular events
[8]. The AIx is a parameter that mainly describes wave
reflections [33]. In healthy vessels the reflected waves
augment diastolic pressure in the aortic root and hence
increase coronary blood flow; however, in the case of
stiffened arteries, waves arrive earlier in systole and
Fig. 1 The association between car-fem PWV and serum urea level (rho = 0.290, p = 0.046)
Fig. 2 The association between central systolic pressure and serum urea level (rho = 0.318, p = 0.029)
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increase end-systolic pressure [33]. Measurements of
central blood pressure have been found to be a better
predictor of future cardiovascular events than brachial
blood pressure [34]. Furthermore, there is evidence that
central blood pressure is more closely related to end-
organ damage than peripheral blood pressure [35–37].
The C2 describes primarily wave reflections that are pro-
duced by small arteries and branching points [37] and
has been shown to independently predict mortality and
future cardiovascular events [31, 38].
In our study we found significantly higher car-fem
PWV in the OA patients compared to the apparently
healthy controls of approximately the same age and with
similar BMI. Since there were no differences in blood
pressure or the proportion of hypertensive subjects, the
effect of hypertension on arterial stiffness was similar in
both study groups. Arterial stiffness parameters have
rarely been studied in OA patients. Saleh et al. [9] found
association between hand OA and car-fem PWV but it
was largely attributable to the confounding effect of age.
Goldsmith et al. [10] found no difference in arterial stiff-
ness between subjects with and without knee bone mar-
row lesions. The discrepancy between the above results
and those of the current study could be explained by the
fact that our patients had a more advanced stage of OA.
Due to pain and functional disability, the level of phys-
ical activity is limited in the advanced stages of OA.
Since physical activity is associated with arterial stiffness
[39], increased pain and higher functional disability sta-
tus might explain increased arterial stiffness in OA pa-
tients. In support of our hypothesis, a recent study has
also found elevated stiffness of the aorta in end-stage
OA patients [40]. Many factors, such as reduced physical
activity, inflammation and oxidative stress, which are
present across end-stage OA patients might be respon-
sible for the stiffer arteries. Obesity is a known risk fac-
tor of both OA and CVD; Adipokines (white adipose
tissue derived hormones) are associated with CVD and
have also been shown to play an important role in OA
development and progression, which allows to link OA
with obesity. Aging is another potential link between
OA and CVD. Accumulation of advanced glycation end-
products is a feature of aging that is present in both
diseases [41, 42].
Although OA has generally been considered a non-
inflammatory condition, the role of inflammation is in-
creasingly being recognised [43–45]. We found in-
creased level of hsCRP in OA patients. The hsCRP is a
marker of low-grade systemic inflammation and has
been shown to increase in OA [43]. In addition, inflam-
mation and elevated levels of hsCRP have been directly
associated with arterial stiffness [16] and increased car-
diovascular risk [31]. Oxidative stress has also been
found to be related to arterial stiffness and endothelial
dysfunction [16]. Analogously, there is evidence to sug-
gest that oxidative stress is involved in the pathogenesis
of OA by causing chondrocyte senescence and apoptosis
[13]. We found a significantly higher level of oxidative
stress index in patients with OA compared to healthy
controls (paper in preparation), which is in line with
previous results and with the hypothesis that oxidative
stress might be at least partly responsible for the in-
creased arterial stiffness in OA.
A number of studies have demonstrated higher CVD
prevalence among OA patients [4, 6]. One plausible ex-
planation for the association of CVD with OA is that
vascular pathology plays a role in development of OA.
Vascular damage to the subchondral bone has been pro-
posed as a possible initiator of OA [46]. Blood supply to
the subchondral bone region may be disturbed by micro-
emboli and venous stasis. Highly vascularized epiphysis is
mainly supplied with blood via the epiphyseal artery,
which makes this region of high nutrient demand particu-
larly susceptible to perfusion insufficiencies. In support of
this hypothesis, Chang et al. [47] found evidence that oste-
oblasts and chondrocytes from osteoarthritic joints suffer
from hypoxia. Furthermore, they also found that hypoxia
induced production of matrix metalloproteinase 9 and
proangiogenic factors and caused reduction in osteoblast
mineralized bone nodule formation, which are all charac-
teristic of OA. Whilst the hypothesis of vascular involve-
ment in OA pathology is gaining support, the potential
role of increased arterial stiffness in OA patients’ in-
creased cardiovascular risk remains unclear.
We found car-fem PWV to be positively correlated
with urea in OA patients. Since urea is the end-product
of amino acid metabolism, this association highlights the
possible role of altered amino acid metabolism in OA
patients. Changes in amino acid profiles and impaired
kidney function have been shown to contribute to in-
creased arterial stiffness [48, 49]. On the basis of eGFR
levels, which were approximately the same across both
groups in this study, there was no difference in the kid-
ney function. After adjusting for the effects of age and
mean pressure, the association between urea and car-
fem PWV was no longer significant. Higher applied
forces (higher blood pressure) in aorta and aging is a
strong independent predictors of car-fem PWV [50]. It
Table 3 Multiple regression analysis with carotid-femoral pulse
wave velocity as dependent variable (adjusted R2 = 0.48), n = 97
Regression coefficient β SE p-value
Constant −6.68 1.81 <0.001
Age 0.15 0.53 0.02 <0.001
Mean pressure 0.07 0.36 0.01 <0.001
OA status 0.74 0.17 0.33 0.029
Urea −1.20 −0.09 0.10 0.233
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is therefore important to adjust for mean pressure and
age when evaluating predictors of car-fem PWV. In the
present study, the association between urea level and
car-fem PWV was largely due to the confounding effects
of age and mean arterial blood pressure. Additional ana-
lysis exploring the effects of body composition, smoking
status, functional status and use of anti inflammatory
drugs on arterial stiffness in OA patients should be
within the scope of future studies.
This study had several limitations that need to be
recognised. First, because of the cross-sectional design
of this study, it was not possible to establish causal asso-
ciations between OA and arterial stiffness. Second, since
no radiographs were taken in the control group, some of
the controls might have had asymptomatic OA and a
type II error might have been introduced. Third, this
study had a relatively small sample size and hence lim-
ited statistical power; concequently, the results need to
be verified by larger studies. Fourth, this study did not
account for effects of the body composition, smoking
status, functional status or use of anti inflammatory
drugs, which might influence arterial stiffness.
Conclusions
In conclusion, our results provide evidence that patients
with end-stage OA have increased central arterial stiff-
ness. Arterial stiffness might be important regarding the
development of OA and increased cardiovascular risk.
However, causal association between OA and vascular
stiffness needs to be confirmed by larger-scale studies.
Acknowledgements
We thank Pirja Sarap, who contributed to the radiographic evaluation of the
OA patients.
Funding
This study was supported by grants of the Estonian Science Foundation
[No. 9094] by Personal Institutional Research Funding (GMVBS1169), by
Institutional Research Funding No IUT20-42 from the Estonian Ministry of
Education and by the European Union through the European Regional
Development Fund (Project No. 2014–2020.4.01.15-0012).
Availability of data and materials
All the data that supports this study is contained within the manuscript.
Requests for further detail on the dataset may be submitted to the
corresponding author.
Authors’ contributions
K. T., A. M., M. Z. and J. K. contributed to the conception and design of the study.
K. T., M. Z., J. K., K. P. and A. M. participated in the acquisition and/or analysis of
data. All authors contributed to data interpretation, drafting and revising the
manuscript, plus approved the submitted version of the manuscript.
Competing interests
The authors have declared no conflicts of interest.
Consent to publish
Not applicable.
Ethics approval and consent to participate
The study was conducted according to the Helsinki declaration and received
approval from the Ethics Committee of the University of Tartu. Written
informed consent was obtained from all participants.
Author details
1Department of Traumatology and Orthopaedics, University of Tartu,
Puusepa street 8, Tartu, Estonia. 2Clinic of Traumatology and Orthopaedics,
Tartu University Hospital, Tartu, Estonia. 3Institute of Biomedicine and
Translational Medicine, Centre of Excellence for Genomics and Translational
Medicine, University of Tartu, Tartu, Estonia. 4Department of Vascular Surgery,
Tartu University Hospital, Tartu, Estonia. 5Department of Surgery, University of
Tartu, Tartu, Estonia.
Received: 11 December 2015 Accepted: 3 August 2016
References
1. Litwic A, Edwards M, Dennison E, Cooper C. Epidemiology and burden of
osteoarthritis. Br Med Bull. 2013;105:185–99.
2. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years
lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries
1990–2010: a systematic analysis for the global burden of disease study
2010. Lancet. 2012;380:2163–96.
3. Hochberg M. Mortality in osteoarthritis. Clin Exp Rheumatol. 2008;26:120.
4. Barbour KE, Lui LY, Nevitt MC, Murphy LB, Helmick CG, Theis KA, et al. Hip
osteoarthritis and the risk of all-cause and disease-specific mortality in older
women: population-based cohort study. Arthritis Rheumatol. 2015;67:1798–805.
5. Gordon M, Rysinska A, Garland A, Rolfson O, Aspberg S, Eisler T, Garellick G,
Stark A, Hailer NP, Sköldenberg O. Increased long-term cardiovascular risk
after total hip arthroplasty: a nationwide cohort study. Medicine (Baltimore).
2016;95:e2662. doi:10.1097/MD.0000000000002662.
6. Rahman MM, Kopec JA, Anis AH, Cibere J, Goldsmith CH. Risk of
cardiovascular disease in patients with osteoarthritis: a prospective
longitudinal study. Arthritis Care Res. 2013;65:1951–8.
7. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular
events and all-cause mortality with arterial stiffness: a systematic review and
meta-analysis. J Am Coll Cardiol. 2010;30;55:1318-27. doi:10.1016/j.jacc.2009.
10.061.
8. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic
stiffness is an independent predictor of all-cause and cardiovascular
mortality in hypertensive patients. Hypertension. 2001;37:1236–41.
9. Saleh AS, Najjar SS, Muller DC, Shetty V, Ferrucci L, Gelber AC, et al. Arterial
stiffness and hand osteoarthritis: a novel relationship? Osteoarthr Cartil.
2007;15:357–61.
10. Goldsmith GM, Aitken D, Cicuttini FM, Wluka AE, Winzenberg T, Ding CH,
et al. Osteoarthritis bone marrow lesions at the knee and large artery
characteristics. Osteoarthr Cartil. 2014;22:91–4.
11. Davies CM, Guilak F, Weinberg JB, Fermor B. Reactive nitrogen and oxygen
species in interleukin-1-mediated DNA damage associated with
osteoarthritis. Osteoarthr Cartil. 2008;16:624–30.
12. Ziskoven C, Jäger M, Zilkens C, Bloch W, Brixius K, Krauspe R. Oxidative stress
in secondary osteoarthritis: from cartilage destruction to clinical
presentation? Orthop Rev. 2010;2:e23.
13. Altay MA, Ertürk C, Bilge A, Yaptı M, Levent A, Aksoy N. Evaluation of
prolidase activity and oxidative status in patients with knee osteoarthritis:
relationships with radiographic severity and clinical parameters. Rheumatol
Int. 2015;21 [Epub ahead of print].
14. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of
proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev
Rheumatol. 2011;7:33–42.
15. Sokolove J, Lepus CM. Role of inflammation in the pathogenesis of
osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet
Dis. 2013;5:77–94.
16. Kals J, Kampus P, Kals M, Pulges A, Teesalu R, Zilmer K, Kullisaar T, Salum T,
Eha J, Zilmer M. Inflammation and oxidative stress are associated differently
with endothelial function and arterial stiffness in healthy subjects and in
patients with atherosclerosis. Scand J Clin Lab Invest. 2008;68:594–601.
17. Lessiani G, Santilli F, Boccatonda A, Iodice P, Liani R, Tripaldi R, Saggini R,
Davì G. Arterial stiffness and sedentary lifestyle: role of oxidative stress.
Vascul Pharmacol. 2015;2 [Epub ahead of print].
Tootsi et al. BMC Musculoskeletal Disorders  (2016) 17:335 Page 7 of 8
18. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in
essential hypertension. Hypertension. 2005;46:1118–22.
19. Kals J, Zagura M, Serg M, Kampus P, Zilmer K, Unt E, Lieberg J, Eha J,
Peetsalu A, Zilmer M. β2-microglobulin, a novel biomarker of peripheral
arterial disease, independently predicts aortic stiffness in these patients.
Scand J Clin Lab Invest. 2011;71:257–63.
20. Thijssen E, van Caam A, van der Kraan PM. Obesity and osteoarthritis, more
than just wear and tear: pivotal roles for inflamed adipose tissue and
dyslipidaemia in obesity-induced osteoarthritis. Rheumatology (Oxford).
2015;54:588–600. doi:10.1093/rheumatology/keu464.
21. Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of
inflammation and metabolism in obesity-related cardiovascular disease.
J Am Coll Cardiol. 2008;7(52):1201–10. doi:10.1016/j.jacc.2008.05.060.
22. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al.
The American College of Rheumatology criteria for the classification and
reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34:505–14.
23. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. The
American College of Rheumatology criteria for the classification and
reporting of osteoarthritis of the knee. Arthritis Rheum. 1986;29:1039–49.
24. Peat G, Thomas E, Duncan R, Wood L. Is a “false-positive” clinical diagnosis
of knee osteoarthritis just the early diagnosis of pre–radiographic disease?
Arthritis Care Res. 2010;62:1502–6.
25. Cubukcu D, Sarsan A, Alkan H. Relationships between pain function and
radiographic findings in osteoarthritis of the knee: a cross-sectional study.
Arthritis. 2012;2012:984060.
26. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR, et al.
Reproducibility of pulse wave velocity and augmentation index measured
by pulse wave analysis. J Hypertens. 1998;16:2079–84.
27. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann
Rheum Dis. 1957;16:494–502.
28. Nichols WW, O'Rourke MF. McDonald’s blood flow in arteries: theoretic,
experimental and clinical principles. 5th ed. London: Edward Arnold; 2005.
29. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML,
Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease
and stroke: the Rotterdam study. Circulation. 2006;113:657–63.
30. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, et al.
Aortic stiffness is an independent predictor of primary coronary events
inhypertensive patients: a longitudinal study. Hypertension. 2002;39:10–5.
31. Kals J, Lieberg J, Kampus P, Zagura M, Eha J, Zilmer M. Prognostic impact of
arterial stiffness in patients with symptomatic peripheral arterial disease.
Eur J Vasc Endovasc Surg. 2014;48:308–15.
32. Townsend RR, Wilkinson IB, Schiffrin EL, Avolio AP, Chirinos JA, Cockcroft JR,
et al. Recommendations for improving and standardizing vascular research
on arterial stiffness: a scientific statement from the American Heart
Association. Hypertension. 2015;66:698–722.
33. Nichols WW, Edwards DG. Arterial elastance and wave reflection
augmentation of systolic blood pressure: deleterious effects and
implications for therapy. J Cardiovasc Pharmacol Ther. 2001;6:5–21.
34. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K,
Stefanadis C. Prediction of cardiovascular events and all-cause mortality
with central hemodynamics: a systematic review and meta-analysis. Eur
Heart J. 2010;31:1865–71.
35. Pini R, Cavallini MC, Palmieri V, Marchionni N, Di Bari M, Devereux RB, et al.
Central but not brachial blood pressure predicts cardiovascular events in an
unselected geriatric population: the ICARe dicomano study. J Am Coll
Cardiol. 2008;51:2432–9.
36. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, et al.
Central pressure more strongly relates to vascular disease and outcome
than does brachial pressure: the strong heart study. Hypertension. 2007;
50:197–203.
37. Duprez DA, De Buyzere MM, De Bruyne L, Clement DL, Cohn JN. Small and
large artery elasticity indices in peripheral arterial occlusive disease (PAOD).
Vasc Med. 2001;6:211–4.
38. Wan Z, Liu X, Wang X, Liu F, Liu W, Wu Y, et al. Small artery elasticity
predicts future cardiovascular events in chinese patients with angiographic
coronary artery disease. Angiology. 2014;65:298–302.
39. Ashor AW, Lara J, Siervo M, Celis-Morales C, Mathers JC. Effects of exercise
modalities on arterial stiffness and wave reflection: a systematic review and
meta-analysis of randomized controlled trials. PLoS ONE. 2014;9:e110034.
40. Belen E, Karaman O, Caliskan G, Atamaner O, Aslan O. Impaired aortic elastic
properties in primary osteoarthritis. Vascular. 2015;0:1–8.
41. Li Y, Wei X, Zhou J, Wei L. The age-related changes in cartilage and
osteoarthritis. BioMed Res Int. 2013;2013:916530.
42. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end
products: sparking the development of diabetic vascular injury. Circulation.
2006;114:597–605.
43. Pearle AD, Scanzello CR, George S, Mandl LA, Dicarlo EF, Peterson M, Sculco
TP, Crow MK. Elevated high-sensitivity C-reactive protein levels are
associated with local inflammatory findings in patients with osteoarthritis.
Osteoarthr Cartil. 2007;15:516–23.
44. Houard X, Goldring MB, Berenbaum F. Homeostatic mechanisms in articular
cartilage and role of inflammation in osteoarthritis. Curr Rheumatol Rep.
2013;15:375.
45. Liu-Bryan R, Terkeltaub R. Emerging regulators of the inflammatory process
in osteoarthritis. Nat Rev Rheumatol. 2015;11:35–44.
46. Findlay DM. Vascular pathology and osteoarthritis. Rheumatology (Oxford).
2007;46:1763–8.
47. Chang J, Jackson SG, Wardale J, Jones SW. Hypoxia modulates the phenotype of
osteoblasts isolated from knee osteoarthritis patients, leading to
undermineralized bone nodule formation. Arthritis Rheumatol. 2014;66:1789–99.
48. Jung S, Kim OY, Kim M, Song J, Lee SH, Lee JH. Age-related increase in
alanine aminotransferase correlates with elevated levels of plasma amino
acids, decanoylcarnitine, Lp-PLA2 Activity, oxidative stress, and arterial
stiffness. J Proteome Res. 2014;13:3467–75.
49. Chue CD, Townend JN, Steeds RP, Ferro CJ. Arterial stiffness in chronic
kidney disease: causes and consequences. Postgrad Med J. 2010;86:560–6.
50. Mceniery CM, Wilkinson IB, Avolio AP. Age, hypertension and arterial
function. Clin Exp Pharmacol Physiol. 2007;34:665–71.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Tootsi et al. BMC Musculoskeletal Disorders  (2016) 17:335 Page 8 of 8
